{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:37:12Z","timestamp":1769330232558,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003975","name":"Israel Cancer Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.eprac.2020.11.004","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T13:41:30Z","timestamp":1609422090000},"page":"34-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["PD-L1 Expression in Normal Endocrine Tissues Is Not Increased Despite High Incidence of PD-1 Inhibitor-Associated Endocrinopathies"],"prefix":"10.1016","volume":"27","author":[{"given":"Rena","family":"Pollack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maayan","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rivka","family":"Dresner-Pollak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzahi","family":"Neuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.eprac.2020.11.004_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2020.11.004_bib2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.eprac.2020.11.004_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"issue":"1","key":"10.1016\/j.eprac.2020.11.004_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.eprac.2020.11.004_bib5","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1016\/j.eprac.2020.11.004_bib6","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline TSH level is associated with risk of anti-PD-1-induced thyroid dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2020.11.004_bib7","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.5_suppl.98","article-title":"The real-world incidence of immunotherapy-related thyroid dysfunction: a retrospective analysis of a single center\u2019s experience over five years","volume":"38","author":"Brody","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.eprac.2020.11.004_bib8","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/cen.13297","article-title":"Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.eprac.2020.11.004_bib9","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.jtho.2016.08.146","article-title":"A\u00a0harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana\u2019s platform","volume":"11","author":"Neuman","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"31","key":"10.1016\/j.eprac.2020.11.004_bib10","doi-asserted-by":"crossref","first-page":"51936","DOI":"10.18632\/oncotarget.17232","article-title":"PD1 signal transduction pathways in T cells","volume":"8","author":"Arasanz","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.eprac.2020.11.004_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.eprac.2020.11.004_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for\u00a0the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"issue":"10","key":"10.1016\/j.eprac.2020.11.004_bib13","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1007\/s12325-019-01051-z","article-title":"Existing and emerging biomarkers for immune checkpoint immunotherapy in solid tumors","volume":"36","author":"Arora","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2020.11.004_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eclinm.2019.03.003","article-title":"Microbiome transplantation and modulation of immune related adverse events","volume":"8","author":"Smibert","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"47","key":"10.1016\/j.eprac.2020.11.004_bib15","doi-asserted-by":"crossref","first-page":"76565","DOI":"10.18632\/oncotarget.12088","article-title":"Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors","volume":"7","author":"Mei","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.eprac.2020.11.004_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11060-018-2844-2","article-title":"The expression profile of PD-L1 and CD8+ lymphocyte in pituitary adenomas indicating for immunotherapy","volume":"139","author":"Wang","year":"2018","journal-title":"J\u00a0Neurooncol"},{"issue":"10","key":"10.1016\/j.eprac.2020.11.004_bib17","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00262-020-02611-x","article-title":"Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor","volume":"69","author":"Suteau","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.eprac.2020.11.004_bib18","doi-asserted-by":"crossref","first-page":"32318","DOI":"10.18632\/oncotarget.8698","article-title":"Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.eprac.2020.11.004_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12022-018-9540-9","article-title":"Papillary thyroid carcinoma emerging from Hashimoto thyroiditis demonstrates increased PD-L1 expression, which persists with metastasis","volume":"29","author":"Lubin","year":"2018","journal-title":"Endocr Pathol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20483181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:07:27Z","timestamp":1761516447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20483181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1530891X20483181"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2020.11.004","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 Expression in Normal Endocrine Tissues Is Not Increased Despite High Incidence of PD-1 Inhibitor-Associated Endocrinopathies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2020.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}